Self-Administered Parenteral Global Market Report 2024

The self-administered parenteral market size has grown strongly in recent years. It will grow from $23.14 billion in 2023 to $24.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historical period can be attributed to several factors, including the increase in chronic diseases, the aging population, government initiatives aimed at healthcare improvement, patient education and support programs, as well as the rising incidences of bone disorders.

The self-administered parenteral market size is expected to see steady growth in the next few years. It will grow to $29.8 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth projected for the forecast period can be attributed to several factors, including the rising preference among patients for home healthcare, telemedicine, and remote patient monitoring, as well as initiatives focused on patient education and support, and the expanding field of personalized medicine. Major trends expected during this period include the integration of digital health solutions, the development of customized drug delivery systems, the emergence of targeted therapies, and advancements in biologics.

The projected rise in chronic diseases is anticipated to drive the expansion of the self-administered parenteral market in the future. Chronic diseases are enduring medical conditions characterized by slow progression and necessitate ongoing management and treatment. Self-administered parenteral products play a crucial role in managing chronic diseases by enabling individuals to independently administer treatment, thereby significantly enhancing adherence compared to oral medication. For instance, data from the National Institutes of Health in January 2023 revealed that among individuals aged 50 or older, the prevalence of at least one chronic disease is expected to surge by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Consequently, the escalating incidence of chronic diseases serves as a key driver fueling the growth of the self-administered parenteral market.

Major players in the self-administered parenteral market are concentrating on the development of innovative products such as the UDENYCA autoinjector to enhance patient choice and control, thereby improving treatment accessibility. An autoinjector is a medical device engineered to deliver a single dose of a specific drug, featuring an intuitive design where administration is triggered immediately and reliably by push-on-skin activation. For instance, in May 2023, Coherus BioSciences Inc., a US-based biotech company, introduced the UDENYCA autoinjector, a self-administered parenteral medication in the US market. The UDENYCA Autoinjector is a single-dose, prefilled autoinjector offering patients an additional administration option for pegfilgrastim. Its intuitive design, activated by push-on-skin, ensures reliable and immediate delivery of a full pegfilgrastim dose. Moreover, it incorporates various user-friendly features such as rapid dosing, intuitive design, dual coverage for at-home and in-office use, and a reduction in the risk of febrile neutropenia, thereby enhancing the overall treatment experience.

In May 2022, Halozyme Therapeutics Inc., a biotechnology company headquartered in the United States, finalized the acquisition of Antares Pharma Inc. for $960 million. Through this transaction, Halozyme aims to leverage Antares' foundational platform technologies and capabilities, intending to establish a leading specialty product and medicine delivery company by expanding its portfolio in this sector. Antares Pharma Inc., also based in the US, specializes in the manufacturing of self-administered parenteral medications.

Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG.

North America was the largest region in the self-administered parenteral market in 2023. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-administered parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Self-administered parenteral refers to the practice of administering medication or ssubstances directly into the body through injection methods by the individual themselves. This approach grants patients increased independence and convenience, enabling them to manage their conditions in a flexible and comfortable manner without frequent visits to healthcare facilities.

The primary products in self-administered parenterals include pre-filled syringes, autoinjectors, pen injectors, and others. Pre-filled syringes are pre-loaded medical devices designed for the delivery of liquid medications. They are available as both disposable and reusable options and are distributed through various channels including hospital pharmacies, online pharmacies, home healthcare providers, specialty clinics, among others. These products are utilized in the treatment of conditions such as cardiovascular diseases, diabetes, osteoporosis, pain management, hormone replacement therapy, and others.

The self-administered parenteral market research report is one of a series of new reports that provides self-administered parenteral market statistics, including self-administered parenteral industry global market size, regional shares, competitors with a self-administered parenteral market share, detailed self-administered parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the self-administered parenteral industry. This self-administered parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The self-administered parenteral market consists of sales of biologic drugs, blood thinners, fertility drugs, osteoporosis medications, and insulin and inhaler devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.